Biointron的动态

Are molecular glue degraders having their moment? In BioSpace, Mark Foundation CEO Ryan Schoenfeld shares why he thinks we’re at an inflection point for this promising drug class.

I enjoyed speaking with Kate Goodwin?from BioSpace?last week about the rising interest in molecular glue degraders (MDG) and their potential to treat cancer and other diseases that were once considered untreatable. The level of investment this year alone from major pharmaceutical companies like Novartis, Biogen, Takeda and Novo Nordisk signals optimism for the promise MGDs hold in creating more precise, effective, and safe therapeutics. Read the full interview here: https://lnkd.in/eCueRFPf.

A Stellar Year for Molecular Glues: Another Billion BioBucks Deal ? The recent surge in investments for molecular glue degraders follows key PROTAC deals, including Arvinas’ $225 million partnership with Pfizer and AstraZeneca’s $1 billion collaboration with C4 Therapeutics, Inc. In 2024, major deals include: ? October 2024 - Pfizer’s $1.5 billion agreement with TRIANA Biomedicines https://lnkd.in/g_MaZYG5 August 2024 - Eisai Co., Ltd.’s $1.5 billion partnership with Seed Therapeutics https://lnkd.in/gSNqDWk7 May 2024 - Takeda’s $1.2 billion collaboration with Degron Therapeutics https://lnkd.in/g-BTJbip February 2024 - Bristol Myers Squibb and VantAI's $674 million deal https://lnkd.in/g3uQhFp5 Novo Nordisk’s $1.46 billion agreement with Neomorph, Inc. https://lnkd.in/gJrd3T4w ? Molecular glues and PROTACs (Proteolysis Targeting Chimeras) are groundbreaking approaches in targeted protein degradation. Molecular glues enhance interactions between target proteins and E3 ligases, while PROTACs link them for degradation, both addressing previously "undruggable" targets. ? These developments underscore the growing potential of these innovative therapies. ? #MolecularGlues #PROTACs #DrugDiscovery

Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody. The planned greenfield facility, supported by the Singapore Econom... https://buff.ly/3V3WJT0 Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody. The planned greenfield facility, supported by the Singapore Econom... #pharma #biotech #lifesciences #clinicalresearch #news #pharmiweb

Antibody Drug Conjugates Contract Manufacturing Antibody-drug conjugates (ADCs) are a class of targeted cancer therapies that combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs. These agents are designed to selectively deliver chemotherapy directly to cancer cells, reducing the damage to healthy tissues. ADCs have become a significant focus in oncology due to their enhanced precision in targeting tumor cells while minimizing systemic toxicity. Contract manufacturing for ADCs involves outsourcing the production of these complex biologic therapies to third-party manufacturers that specialize in the development, production, and scale-up of biologics. The process includes several critical stages Visti Us- https://lnkd.in/eyPaMpf5 |Lonza |Merck KGaA, Darmstadt, Germany|Recipharm|Thermo Fisher Scientific|AbbVie|Piramal Pharma Solutions|Catalent Pharma Solutions|Sterling Pharma Solutions|Curia|Novasep|Ajinomoto Bio-Pharma Services|BSP Pharmaceuticals S.p.A.|Cerbios-Pharma SA|Goodwin Biotechnology #Antibody #Drug #Conjugates #Contract #Manufacturing

Great news from Orum Therapeutics, a #Korea based #biotech has been just announced. It is filing for an initial public offering (IPO) on South Korea's #Kosdaq market. https://lnkd.in/eUW_D-_2 Company is focusing it innovation pipeline on degrader-antibody conjugates (#DACs). Orum’s proprietary Dual-precision Targeted Protein Degradation (TPD) approach uses antibodies to deliver small molecule targeted protein degrader payloads to targeted cancer cells. The TPD technology produced two most advanced products. ORM-5029 (targets #HER2) and ORM-6151 (targets #CD33 and acquired by BMS). Great news and very interesting potential for the new therapeutic modality. South Korea's biotech industry is definitively experiencing rapid growth.

Happy Friday network! There has been quite a number of significant movements across the life science space over the last few weeks, wanted to highlight the few of you who may not be aware. Sanofi pays over $100 million upfront for neuroendocrine tumor RLT therapy: https://lnkd.in/ebfrv4cw Moderna aims to cut $1.1 billion in spending, cutting 5 programs with potentially more to come:?https://lnkd.in/e9HKqZkR Bain Capital reveal $3 billion funding round to make big investment moves in biotech:?https://lnkd.in/euG2Pwe6 Gilead Sciences pays Genesis Therapeutics $35 million for AI based drug discovery work: https://lnkd.in/eKruqapY #pharma #biotech #lifescience #biotechinvestment

#BioBDHighlights ?? On December 29th, Hengrui Pharma Co.,Ltd announced that it has granted an exclusive, compensated license to #IDEAYA Biosciences for the global development, production, and commercialization (outside Greater China) of its proprietary Delta-like ligand 3 (#DLL3) ADC innovative drug SHR-4849. ?? Financial Terms: Under the agreement, IDEAYA Biosciences will make an upfront payment of $75 million to Hengrui Pharmaceuticals. The potential milestone payments include up to $200 million for R&D achievements and up to $770 million for sales milestones, totaling a potential sum of $1.045 billion. Additionally, Hengrui Pharmaceuticals will receive a sales royalty based on a percentage of actual annual net sales. ?? About IDEAYA Biosciences: Founded in 2015, IDEAYA Biosciences is a precision oncology company based in South San Francisco, USA. The company went public on the #NASDAQ in 2019 (Ticker: IDYA). IDEAYA is committed to developing precision-targeted therapies for patients identified through molecular diagnostics, combining the discovery and validation of translatable biomarkers with drug development to select the most promising patient populations for targeted therapies. ?? About SHR-4849: SHR-4849 is an #ADC targeting DLL3, an antigen expressed in several solid tumors, including small cell lung cancer and #neuroendocrine tumors, but with limited expression in normal tissues. The payload of SHR-4849 is a #topoisomerase inhibitor (TOPOi). This ADC demonstrates strong #antiproliferative activity against #DLL3-positive tumor cell lines and shows bystander effects, enabling the release of toxins to kill DLL3-low-expressing cells. Currently, no DLL3 ADC products have been approved globally. ?? Innovative Collaboration in Oncology: This partnership marks a significant step in the development of cutting-edge cancer treatments. With SHR-4849 at the forefront, this collaboration opens new pathways for precision oncology targeting DLL3. #Oncology #ADC #Biopharma #PrecisionMedicine #Innovation #Pharmaceuticals #Partnership #Biotech #MolecularDiagnostics #TargetedTherapy #HengruiPharmaceuticals #IDEAYABiosciences #CancerResearch

Ikena Oncology and Inmagene Biopharma have announced a merger to form ImageneBio, focusing on developing IMG-007, a monoclonal antibody targeting OX40 for atopic dermatitis treatment. The merger is supported by a $75 million private placement from new and existing investors, including Deep Track Capital, Foresite Capital, and BVF Partners. ImageneBio will be listed on NASDAQ under the ticker IMA. #Pharma #Oncology #Biotech #Biosimilars #PharmaNews #CancerResearch #DrugDevelopment #Healthcare #Biotechnology #PrecisionMedicine #PharmaIndustry #Biopharma #PharmaConsulting #CompetitiveIntelligence #LifeSciencesConsulting Source: https://lnkd.in/gQvEc_q4